Search Results

Early and Midterm Data From GHOST-EU Registry Published

July 18, 2014—EuroIntervention Editor-in-Chief Patrick Serruys, MD, announced the publication of the early and midterm outcomes of GHOST-EU, the largest (N = 1,189) European multicenter experience with the Abbott Vascular Absorb bioresorbable vascular scaffold (BVS) in real-world patients undergoing percutaneous coronary intervention (PCI).

German Registry Documents the Increased Use and Improved Outcomes for TAVR

September 20, 2015—Patrick Serruys, MD, Editor-in-Chief of EuroIntervention, and Darren Mylotte, MD, Associate Editor of EuroIntervention, announced the expedited editorial publication of a study by Holger Eggebrecht MD, and Rajender Mehta, MD, which analyzed the use of transcatheter aortic valve replacement (TAVR) in Germany from 2008 to 2014.

Twelve-Month Results Published From DESSOLVE III Trial of Micell's MiStent

December 6, 2017—Micell Technologies, Inc. announced that 12-month results from the DESSOLVE III clinical trial of the company's MiStent, a sirolimus-eluting bioabsorbable polymer-coated stent, were published by Prof.

GLOBAL LEADERS Trial Presented at ESC Congress

August 27, 2018—The European Society of Cardiology (ESC) announced that findings from the GLOBAL LEADERS trial demonstrated that long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy (DAPT).

Two-Year Data Presented From MiStent DESSOLVE III Trial

May 23, 2018—Micell Technologies, Inc. announced that a 24-month update on the DESSOLVE III trial of the company's MiStent sirolimus-eluting absorbable-polymer coronary stent system was presented by Prof.

First Patient Enrolled in TRANSFORM-1 RCT of Concept Medical’s MagicTouch Sirolimus-Coated Balloon for Small Coronary Vessels

September 2, 2020—Concept Medical Inc. announced the enrollment of the first patient in the TRANSFORM-1 randomized clinical trial (RCT) of the treatment of small coronary vessels with percutaneous coronary intervention (PCI) using the company’s MagicTouch sirolimus-coated balloon.

Medtronic's Resolute Integrity DES Approved for New Indications in Europe

May 15, 2012—At the EuroPCR 2012 conference in Paris, Medtronic, Inc. (Minneapolis, MN) announced that the Resolute Integrity coronary drug-eluting stent (DES) system has received European regulatory approval for several new indications: acute coronary syndrome, acute myocardial infarction, unstable angina, total occlusions and chronic total occlusions, and in-stent restenosis.

Abbott's Xience Prime DES Launched in International Markets

August 31, 2009—At the European Society of Cardiology Congress in Barcelona, Spain, Abbott Vascular (Santa Clara, CA) announced the international launch of its next-generation Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease.

Global SURTAVI Trial Begins for Medtronic's CoreValve System in Intermediate-Risk Patients

July 18, 2012—Medtronic, Inc. (Minneapolis, MN) announced the commencement of enrollment in the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) clinical trial comparing its transcatheter CoreValve system with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk for open heart surgery.

All-Comers Trial Studies Medtronic's Resolute DES

May 25, 2010—Medtronic, Inc. (Minneapolis, MN) announced that the first results of the RESOLUTE All-Comers (AC) study were presented at the 2010 EuroPCR conference in Paris.

Terumo Commences European TROFI Study of Optical Frequency Domain Imaging

November 24, 2010—Terumo Europe NV (Leuven, Belgium) announced the commencement of patient enrollment in the TROFI study, which is seeking to prove the benefits of thrombus aspiration in treating patients with ST-elevation myocardial infarction (STEMI) using the company's optical frequency domain imaging (OFDI) technology.

Medtronic Begins US Enrollment of Intermediate-Risk Patients in Global SURTAVI Trial

November 16, 2012—Medtronic, Inc. (Minneapolis, MN) announced the first treatment of a patient in the United States in its global, multicenter, randomized clinical trial comparing the transcatheter Medtronic CoreValve system with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk to undergo open-heart surgery.

Micell's MiStent Achieves Primary Endpoint in All-Comers DESSOLVE III Trial

May 16, 2017—Micell Technologies, Inc. announced that positive 12-month data from its DESSOLVE III clinical trial were presented by Prof.

SPIRIT Studies Show Abbott Vascular's Xience V Reduces Restenosis and Repeat Revascularization

October 24, 2010—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that new data from the SPIRIT studies have determined that everolimus-eluting stent (EES) implantation reduced the incidence of restenosis and repeat revascularization in patients with calcified culprit lesions, as well as had fewer clinical events.

Data Presented From Pivotal Trial of Cordis' Nevo Stent

May 19, 2009—Cordis Corporation (Warren, NJ) announced that 6-month study results suggest the company's Nevo sirolimus-eluting coronary stent, incorporating RES reservoir technology, was superior to the Taxus Liberté stent (Boston Scientific Corporation, Natick, MA) in reducing tissue growth within the stent that can potentially lead to repeat procedures.

Data Presented From Pivotal Trial of Cordis' Nevo Stent

May 19, 2009—Cordis Corporation (Warren, NJ) announced that 6-month study results suggest the company's Nevo sirolimus-eluting coronary stent, incorporating RES reservoir technology, was superior to the Taxus Liberté stent (Boston Scientific Corporation, Natick, MA) in reducing tissue growth within the stent that can potentially lead to repeat procedures.

Five-Year ARTS II Outcomes Reported for SES

March 16, 2010—Patrick W. Serruys, MD, PhD, et al published findings from a study that sought to compare the 5-year clinical outcomes, safety, and efficacy of sirolimus-eluting stents (SES) in ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of coronary artery bypass grafting (CABG) and bare-metal stents (BMS) from the ARTS I study. The background of the study is that the long-term outcome after SES implantation in patients with multivessel disease had yet to be established. The findings were published in the Journal of the American College of Cardiology (2010;55:1093–1101).